Categories AlphaGraphs, Consumer, Earnings
TPR Earnings: Highlights of Tapestry’s Q1 2024 financial results
Tapestry Inc. (NYSE: TPR), a leading luxury fashion company, on Thursday reported an increase in adjusted earnings for the first quarter of 2024 when sales remained almost unchanged year-over-year.

Adjusted net income was $0.93 per share in the September quarter, higher than the $0.79/share profit reported in the corresponding period of 2023. Unadjusted net income came in at $195 million or $0.84 per share in Q1, vs. $195.3 million or $0.79 per share in the prior-year period.
The company generated $1.51 billion in net sales during the three-month period, which is broadly unchanged from the prior-year quarter. It achieved International revenue growth of 7% at constant currency, fueled by gains in Japan and Greater China.
Joanne Crevoiserat, Tapestry’s CEO, said, “We achieved record first-quarter revenue and EPS as we continued to successfully advance our strategic growth agenda against a dynamic external backdrop. Our strong and consistent results demonstrate the power of brand building and customer centricity, underpinned by the creativity of our talented global teams and disciplined execution.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
